MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin

被引:130
作者
Roulet, A
Puel, O
Gesta, S
Lepage, JF
Drag, M
Soll, M
Alvinerie, M
Pineau, T
机构
[1] INRA, Lab Pharmacol & Toxicol, F-31931 Toulouse 9, France
[2] MERIAL R&D, Duluth, GA USA
关键词
ivermectin; (dog); (collie); hypersensitivity; P-glycoprotein; MDR (multidrug resistance);
D O I
10.1016/S0014-2999(02)02955-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Multidrug resistance (MDR) phenotypes in cancer cells are associated with overexpression of the drug carrier P-glycoprotein. The antiparasitic drug ivermectin, one of its substrates, abnormally accumulates in the brain of transgenic mice lacking the P-glycoprotein, resulting in neurotoxicity. Similarly, an enhanced sensitivity to ivermectin has been reported in certain dogs of the Collie breed. To explore the basis of this phenotype, we analyzed the canine P-glycoprotein-encoding MDR1 gene, and we report the first characterization of the cDNA for wild-type (Beagle) P-glycoprotein. The corresponding transcripts from ivermectin-sensitive Collies revealed a homozygous 4-bp exonic deletion. We established, by genetic testings, that the MDR1 frame shift is predictable. Accordingly, no P-glycoprotein was detected in the homozygote-deficient dogs. In conclusion, we characterized a unique case of naturally occurring gene invalidation. This provides a putative novel model that remains to be exploited in the field of human therapeutics and that might significantly affect tissue distribution and drug bioavailability studies. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:85 / 91
页数:7
相关论文
共 26 条
[1]   IVERMECTIN - A REVIEW OF EFFICACY AND SAFETY [J].
CAMPBELL, WC ;
BENZ, GW .
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS, 1984, 7 (01) :1-16
[2]   IVERMECTIN, AN ANTIPARASITIC AGENT [J].
CAMPBELL, WC .
MEDICINAL RESEARCH REVIEWS, 1993, 13 (01) :61-79
[3]   Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1 [J].
Conrad, S ;
Viertelhaus, A ;
Orzechowski, A ;
Hoogstraate, J ;
Gjellan, K ;
Schrenk, D ;
Kauffmann, HM .
TOXICOLOGY, 2001, 156 (2-3) :81-91
[4]   Anthelmintics - A comparative review of their clinical pharmacology [J].
deSilva, N ;
Guyatt, H ;
Bundy, D .
DRUGS, 1997, 53 (05) :769-788
[5]   The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor [J].
Didier, A ;
Loor, F .
ANTI-CANCER DRUGS, 1996, 7 (07) :745-751
[6]   Mechanism of action of p-glycoprotein in relation to passive membrane permeation [J].
Eytan, GD ;
Kuchel, PW .
INTERNATIONAL REVIEW OF CYTOLOGY - A SURVEY OF CELL BIOLOGY, VOL 190, 1999, 190 :175-250
[7]  
FASSLER PE, 1991, J AM VET MED ASSOC, V199, P457
[8]   A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle [J].
Grobet, L ;
Martin, LJR ;
Poncelet, D ;
Pirottin, D ;
Brouwers, B ;
Riquet, J ;
Schoeberlein, A ;
Dunner, S ;
Menissier, F ;
Massabanda, J ;
Fries, R ;
Hanset, R ;
Georges, M .
NATURE GENETICS, 1997, 17 (01) :71-74
[9]   P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity [J].
Lankas, GR ;
Cartwright, ME ;
Umbenhauer, D .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1997, 143 (02) :357-365
[10]  
LEVEILLEWEBSTER CR, 1995, J MEMBRANE BIOL, V143, P89